Evidence map›Paper›PMID 39194588›Full record

ReviewBiosensors2024

Far-Red Fluorescent Proteins: Tools for Advancing In Vivo Imaging.

Angyang Shang, Shuai Shao, Luming Zhao, Bo Liu

Abstract readReview
In one paragraph

Review in Biosensors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Angyang ShangCancer Hospital of Dalian University of Technology, Shenyang 110042, China.
Shuai ShaoCancer Hospital of Dalian University of Technology, Shenyang 110042, China.
Luming ZhaoCancer Hospital of Dalian University of Technology, Shenyang 110042, China.ORCID 0000-0003-2944-5882
Bo LiuCancer Hospital of Dalian University of Technology, Shenyang 110042, China.ORCID 0000-0002-5375-0505

Funding

General Program of National Natural Science Foundation of China No. 32071252"Oncology+" Open project of Liaoning Cancer Hospital, China No. 2024-ZLKF-36
6 · The paper itself

Abstract

Far-red fluorescent proteins (FPs) have emerged as indispensable tools in in vivo imaging, playing a pivotal role in elucidating fundamental mechanisms and addressing application issues in biotechnology and biomedical fields. Their ability for deep penetration, coupled with reduced light scattering and absorption, robust resistance to autofluorescence, and diminished phototoxicity, has positioned far-red biosensors at the forefront of non-invasive visualization techniques for observing intracellular activities and intercellular behaviors. In this review, far-red FPs and their applications in living systems are mainly discussed. Firstly, various far-red FPs, characterized by emission peaks spanning from 600 nm to 650 nm, are introduced. This is followed by a detailed presentation of the fundamental principles enabling far-red biosensors to detect biomolecules and environmental changes. Furthermore, the review accentuates the superiority of far-red FPs in multi-color imaging. In addition, significant emphasis is placed on the value of far-red FPs in improving imaging resolution, highlighting their great contribution to the advancement of in vivo imaging.

Indexed as

Biosensing TechniquesLuminescent ProteinsRed Fluorescent ProteinAnimalsHumansOptical ImagingLuminescent ProteinsRed Fluorescent Proteinfar-red fluorescent proteinsfluorescence imagingfluorescent biosensors

Identifiers

PMID39194588
PMCPMC11352758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.